A prospective observational safety study of patients with <scp> BRAF V </scp> 600 ‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)

Pippa Corrie(University of Cambridge), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Dirk Debus(Nuremberg Hospital), Rudolf Herbst(Helios Klinikum Erfurt), Slinger Jansen(Maastricht University Medical Centre), Albert J. ten Tije(Amphia Ziekenhuis), Klaus Freivogel, Grant R. Goodman(Melanoma Institute Australia), Marie Lou Munson, Riccardo Marconcini(Azienda Ospedaliera Universitaria Pisana), Maria Marples(Leeds Teaching Hospitals NHS Trust), Jessie J. Hsu, Patrick Terheyden(University Hospital Schleswig-Holstein), Donald E. Colburn, Natalia Sadetsky

British Journal of Dermatology

November 29, 2018

Cited by 4

|New England Journal of Medicine|2014|5.3k

|The Lancet|2012|3k

|New England Journal of Medicine|2014|2.7k

|New England Journal of Medicine|2017|2.2k

|New England Journal of Medicine|2018|1.9k

A prospective observational safety study of patients with <scp> <i>BRAF</i> <sup>V</sup> </scp> <sup>600</sup> ‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)